Merck Keytruda Rivalry Surges as Ivonescimab Stumbles
Is the latest ivonescimab setback a temporary stumble or a turning point in the Merck Keytruda Rivalry for lung cancer dominance? Maik Kemper Editor in Chief The interim…
AbbVie Earnings +4.5% Surge After Bullish Upgrade Shock
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition? Maik Kemper Editor in Chief Conclusion In summary,…
Eli Lilly GLP-1 pill Foundayo: Can the Boom Last?
Can the new Eli Lilly GLP-1 pill Foundayo justify the stock’s rich valuation and extend its obesity drug dominance? Maik Kemper Editor in Chief Conclusion Overall, the Eli…
Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide
Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to Eli Lilly? Maik Kemper Editor in Chief Conclusion…
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across multiple clinical trials…
Pfizer Lyme vaccine 70% efficacy Shock as PFE slips
Can the Pfizer Lyme vaccine’s >70% efficacy data revive sentiment around PFE just as investors write off its post-COVID growth story? Maik Kemper Editor in Chief Conclusion Overall,…
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in Chief With triple…
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in GLP-1 leaders? Maik Kemper Editor in Chief The…
Merck KGaA Forecast Warning: 2026 Profit Hit Looms
Is the latest Merck KGaA Forecast a temporary setback before new growth, or the start of a longer earnings squeeze? Merck KGaA Forecast: What the 2026 Guidance Really…